Physician profile
Doha Ayish
NPI 1891180253
$6,247.17
in general payments reported to CMS, 2019-2025
43 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $85.72 · 2021: $423 · 2022: $825 · 2023: $1,262 · 2024: $1,736 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,794.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,495.81 | 2021-2025 | Botox, Qulipta, Duopa |
| Pfizer INC. | $450.09 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $313.57 | 2021-2025 | Nuplazid |
| Eisai INC. | $286.28 | 2023-2025 | |
| Abbott Laboratories | $281.50 | 2021-2025 | Infinity, Eterna, Proclaim |
| Lilly USA, LLC | $251.44 | 2022-2024 | Emgality, Amyvid |
| Neurocrine Biosciences, INC. | $230.76 | 2022-2025 | Ingrezza |
| Allergan, INC. | $212.81 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $212.74 | 2021-2025 | Rytary, Crexont |
| Sk Life Science, INC. | $211.95 | 2022-2025 | |
| Argenx US, INC. | $193.18 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $191.45 | 2021-2025 | Rystiggo |
| Teva Pharmaceuticals USA, INC. | $153.22 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Medtronic, INC. | $122.78 | 2023-2025 | Inceptiv, Activa Pc, Intellis Adaptivestim |
| Alexion Pharmaceuticals, INC. | $122.06 | 2022-2025 | Ultomiris |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $107.13 | 2022-2025 | Xeomin |
| Averitas Pharma INC. | $100.73 | 2023-2024 | Qutenza |
| Globus Medical, INC. | $91.57 | 2025 | Senza, Si-Lok, Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $91.40 | 2023-2024 | Hyqvia, Gammagard |
| Upsher-Smith Laboratories LLC | $86.30 | 2020-2023 | |
| Microtransponder, INC. | $83.78 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $82.09 | 2022 | |
| Amgen INC. | $77.88 | 2021-2023 | Repatha |
| Otsuka America Pharmaceutical, INC. | $75.86 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $60.31 | 2021-2022 | |
| Boston Scientific Corporation | $54.21 | 2025 | General - Dbs |
| Corium, LLC | $51.58 | 2023 | Adlarity |
| Grifols USA, LLC | $51.37 | 2023-2024 | Gamunex-C |
| Mdd US Operations, LLC | $48.99 | 2024 | Apokyn |
| Avanir Pharmaceuticals, INC. | $47.65 | 2019 | |
| Supernus Pharmaceuticals, INC. | $45.98 | 2023-2024 | Qelbree |
| Acorda Therapeutics, INC | $45.73 | 2019 | |
| Integra Lifesciences Corporation | $42.76 | 2025 | Codman Certas, Codman Hakim, Cusa Clarity |
| Insightec,INC | $39.40 | 2023-2024 | Exablate |
| Lundbeck LLC | $37.94 | 2024-2025 | Rexulti, Vyepti |
| Biohaven Pharmaceuticals, INC. | $31.21 | 2021 | |
| Janssen Biotech, INC. | $29.47 | 2025 | |
| Livanova USA, INC. | $27.05 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Csl Behring | $26.39 | 2019 | |
| Bioventus LLC | $21.09 | 2025 | Durolane |
| Spr Therapeutics, INC | $20.95 | 2025 | Sprint Pns System |
| Axsome Therapeutics, INC. | $20.31 | 2025 | Symbravo |
| Depuy Synthes Sales INC. | $18.40 | 2025 | Orthovisc, Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doha Ayish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.